Clinical trials for Neuroendocrine tumours

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Neuroendocrine tumours. For all clinical trials, go to clinical trials search

This list shows clinical trials for Neuroendocrine tumours

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Neuroendocrine tumours
Title Recruitment status Location
Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR study) Authorised United Kingdom
A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours - PTK878/ZK 222584 in patients with advanced NET Authorised United Kingdom
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors Authorised United Kingdom
A multicenter, stratified, open, randomized, comparator-controlled, parallelgroup phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours. Authorised United Kingdom
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors Authorised United Kingdom
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors Authorised United Kingdom
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors Authorised United Kingdom
A multicenter, stratified, open, randomized, comparator-controlled, parallelgroup phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours. Authorised United Kingdom
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors Authorised United Kingdom
Randomized not blinded clinical trial to compare two sequences of treatment: STZ-5FU followed by everolimus or everolimus followed by STZ- 5FU upon progression in advanced progressive pancreatic neuroendocrine tumors (SEQTOR study) Authorised United Kingdom

Page last reviewed: 04/11/2014

Next review due: 04/11/2017